These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29562985)

  • 1. Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?
    Htet KKK; Soe KT; Kumar AMV; Saw S; Win Maung HM; Myint Z; Khine TMM; Aung ST
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):385-392. PubMed ID: 29562985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study.
    Htun YM; Khaing TMM; Yin Y; Myint Z; Aung ST; Hlaing TM; Soonthornworasiri N; Silachamroon U; Kasetjaroen Y; Kaewkungwal J
    BMC Health Serv Res; 2018 Nov; 18(1):878. PubMed ID: 30458776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study.
    Htun YM; Khaing TMM; Aung NM; Yin Y; Myint Z; Aung ST; Soonthornworasiri N; Silachamroon U; Kasetjaroen Y; Kaewkungwal J
    PLoS One; 2018; 13(12):e0209932. PubMed ID: 30596734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High treatment success rate among multidrug-resistant tuberculosis patients in Myanmar, 2012-2014: a retrospective cohort study.
    Thu MK; Kumar AMV; Soe KT; Saw S; Thein S; Mynit Z; Maung HMW; Aung ST
    Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):410-417. PubMed ID: 29351672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happened to patients with RMP-resistant/MDR-TB in Zambia reported as lost to follow-up from 2011 to 2014?
    Kasapo CC; Chimzizi R; Simwanza SC; Mzyece J; Chizema E; Mariandyshev A; Lee HY; Harries AD; Kapata N
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):887-893. PubMed ID: 28786797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
    PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
    Ngabonziza JS; Habimana YM; Decroo T; Migambi P; Dushime A; Mazarati JB; Rigouts L; Affolabi D; Ivan E; Meehan CJ; Van Deun A; Fissette K; Habiyambere I; Nyaruhirira AU; Turate I; Semahore JM; Ndjeka N; Muvunyi CM; Condo JU; Gasana M; Hasker E; Torrea G; de Jong BC
    Int J Tuberc Lung Dis; 2020 Mar; 24(3):329-339. PubMed ID: 32228764
    [No Abstract]   [Full Text] [Related]  

  • 9. Pretreatment attrition and treatment initiation delay among rifampicin-resistant tuberculosis patients in Lagos, Nigeria: a retrospective cohort study.
    Adejumo OA; Daniel O; Adepoju VA; Onoh MO; Sokoya OD; Abdur-Razzaq H; Moronfolu O; Oyadotun OM; Olusola-Faleye B
    Trans R Soc Trop Med Hyg; 2022 Dec; 116(12):1154-1161. PubMed ID: 35710310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-resistant tuberculosis in Yangon, Myanmar.
    Phyu S; Lwin T; Ti T; Maung W; Mar WW; Shein SS; Grewal HM
    Scand J Infect Dis; 2005; 37(11-12):846-51. PubMed ID: 16308219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
    Kassa GM; Teferra AS; Wolde HF; Muluneh AG; Merid MW
    BMC Infect Dis; 2019 Sep; 19(1):817. PubMed ID: 31533661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National anti-tuberculosis drug resistance survey, 2002, in Myanmar.
    Ti T; Lwin T; Mar TT; Maung W; Noe P; Htun A; Kluge HH; Wright A; Aziz MA; Paramasivan CN
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1111-6. PubMed ID: 17044203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria- A retrospective cohort study.
    Oga-Omenka C; Zarowsky C; Agbaje A; Kuye J; Menzies D
    PLoS One; 2019; 14(4):e0215542. PubMed ID: 31022228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low mother-to-child HIV transmission rate but high loss-to-follow-up among mothers and babies in Mandalay, Myanmar; a cohort study.
    Kyaw KWY; Oo MM; Kyaw NTT; Phyo KH; Aung TK; Mya T; Aung N; Oo HN; Isaakidis P
    PLoS One; 2017; 12(9):e0184426. PubMed ID: 28886165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
    Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
    Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriologically confirmed pulmonary tuberculosis patients: Loss to follow-up, death and delay before treatment initiation in Bulawayo, Zimbabwe from 2012-2016.
    Mugauri H; Shewade HD; Dlodlo RA; Hove S; Sibanda E
    Int J Infect Dis; 2018 Nov; 76():6-13. PubMed ID: 30030177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.
    Mohr E; Daniels J; Beko B; Isaakidis P; Cox V; Steele SJ; Muller O; Snyman L; De Azevedo V; Shroufi A; Trivino Duran L; Hughes J
    PLoS One; 2017; 12(5):e0178054. PubMed ID: 28542441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.
    Seddon JA; Hesseling AC; Marais BJ; Jordaan A; Victor T; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Jul; 16(7):928-33. PubMed ID: 22583610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
    Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.